Trial Profile

Phase I/II clinical trial of therapeutic vaccine containing HBsAg and HBcAg against HBV carrier

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABX 203 (Primary)
Indications Hepatitis B
Focus Therapeutic Use

Most Recent Events

14 Nov 2023 Results assessing long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
15 Nov 2021 Patients of this study enrolled at Ehime University Hospital, Japan, as per results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
15 Nov 2021 Results assessing the efficacy of CVP-NASVAC at 30 months after final injection, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com